

# Biosimilar Insulin-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

<https://marketpublishers.com/r/B1A8EC59F0AEN.html>

Date: December 2017

Pages: 132

Price: US\$ 3,680.00 (Single User License)

ID: B1A8EC59F0AEN

## Abstracts

### Report Summary

Biosimilar Insulin-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Biosimilar Insulin industry, standing on the readers' perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of Biosimilar Insulin 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Biosimilar Insulin worldwide and market share by regions, with company and product introduction, position in the Biosimilar Insulin market  
Market status and development trend of Biosimilar Insulin by types and applications  
Cost and profit status of Biosimilar Insulin, and marketing status  
Market growth drivers and challenges

The report segments the global Biosimilar Insulin market as:

Global Biosimilar Insulin Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)

Asia Pacific (China, Japan, India, Southeast Asia and Australia)

Latin America (Brazil, Argentina and Colombia)

## Middle East and Africa

Global Biosimilar Insulin Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Rapid Acting Insulins

Short Acting Insulins

Intermediate Insulins

Long Lasting Insulins

Global Biosimilar Insulin Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital

Clinic

Medical Center

Global Biosimilar Insulin Market: Manufacturers Segment Analysis (Company and Product introduction, Biosimilar Insulin Sales Volume, Revenue, Price and Gross Margin):

Pfizer

Biogenomics

Eli Lilly

Gan&Lee Pharmaceuticals

Geropharm

Julphar Gulf Pharmaceutical Industries

Paras Biopharmaceuticals

Samsung Bioepis

Sedico

Wockhardt

Teva Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF BIOSIMILAR INSULIN**

- 1.1 Definition of Biosimilar Insulin in This Report
- 1.2 Commercial Types of Biosimilar Insulin
  - 1.2.1 Rapid Acting Insulins
  - 1.2.2 Short Acting Insulins
  - 1.2.3 Intermediate Insulins
  - 1.2.4 Long Lasting Insulins
- 1.3 Downstream Application of Biosimilar Insulin
  - 1.3.1 Hospital
  - 1.3.2 Clinic
  - 1.3.3 Medical Center
- 1.4 Development History of Biosimilar Insulin
- 1.5 Market Status and Trend of Biosimilar Insulin 2013-2023
  - 1.5.1 Global Biosimilar Insulin Market Status and Trend 2013-2023
  - 1.5.2 Regional Biosimilar Insulin Market Status and Trend 2013-2023

### **CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Development of Biosimilar Insulin 2013-2017
- 2.2 Sales Market of Biosimilar Insulin by Regions
  - 2.2.1 Sales Volume of Biosimilar Insulin by Regions
  - 2.2.2 Sales Value of Biosimilar Insulin by Regions
- 2.3 Production Market of Biosimilar Insulin by Regions
- 2.4 Global Market Forecast of Biosimilar Insulin 2018-2023
  - 2.4.1 Global Market Forecast of Biosimilar Insulin 2018-2023
  - 2.4.2 Market Forecast of Biosimilar Insulin by Regions 2018-2023

### **CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Sales Volume of Biosimilar Insulin by Types
- 3.2 Sales Value of Biosimilar Insulin by Types
- 3.3 Market Forecast of Biosimilar Insulin by Types

### **CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Global Sales Volume of Biosimilar Insulin by Downstream Industry
- 4.2 Global Market Forecast of Biosimilar Insulin by Downstream Industry

## **CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 5.1 North America Biosimilar Insulin Market Status by Countries
  - 5.1.1 North America Biosimilar Insulin Sales by Countries (2013-2017)
  - 5.1.2 North America Biosimilar Insulin Revenue by Countries (2013-2017)
  - 5.1.3 United States Biosimilar Insulin Market Status (2013-2017)
  - 5.1.4 Canada Biosimilar Insulin Market Status (2013-2017)
  - 5.1.5 Mexico Biosimilar Insulin Market Status (2013-2017)
- 5.2 North America Biosimilar Insulin Market Status by Manufacturers
- 5.3 North America Biosimilar Insulin Market Status by Type (2013-2017)
  - 5.3.1 North America Biosimilar Insulin Sales by Type (2013-2017)
  - 5.3.2 North America Biosimilar Insulin Revenue by Type (2013-2017)
- 5.4 North America Biosimilar Insulin Market Status by Downstream Industry (2013-2017)

## **CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

- 6.1 Europe Biosimilar Insulin Market Status by Countries
  - 6.1.1 Europe Biosimilar Insulin Sales by Countries (2013-2017)
  - 6.1.2 Europe Biosimilar Insulin Revenue by Countries (2013-2017)
  - 6.1.3 Germany Biosimilar Insulin Market Status (2013-2017)
  - 6.1.4 UK Biosimilar Insulin Market Status (2013-2017)
  - 6.1.5 France Biosimilar Insulin Market Status (2013-2017)
  - 6.1.6 Italy Biosimilar Insulin Market Status (2013-2017)
  - 6.1.7 Russia Biosimilar Insulin Market Status (2013-2017)
  - 6.1.8 Spain Biosimilar Insulin Market Status (2013-2017)
  - 6.1.9 Benelux Biosimilar Insulin Market Status (2013-2017)
- 6.2 Europe Biosimilar Insulin Market Status by Manufacturers
- 6.3 Europe Biosimilar Insulin Market Status by Type (2013-2017)
  - 6.3.1 Europe Biosimilar Insulin Sales by Type (2013-2017)
  - 6.3.2 Europe Biosimilar Insulin Revenue by Type (2013-2017)
- 6.4 Europe Biosimilar Insulin Market Status by Downstream Industry (2013-2017)

## **CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE,**

## **MANUFACTURERS AND DOWNSTREAM INDUSTRY**

### 7.1 Asia Pacific Biosimilar Insulin Market Status by Countries

- 7.1.1 Asia Pacific Biosimilar Insulin Sales by Countries (2013-2017)
- 7.1.2 Asia Pacific Biosimilar Insulin Revenue by Countries (2013-2017)
- 7.1.3 China Biosimilar Insulin Market Status (2013-2017)
- 7.1.4 Japan Biosimilar Insulin Market Status (2013-2017)
- 7.1.5 India Biosimilar Insulin Market Status (2013-2017)
- 7.1.6 Southeast Asia Biosimilar Insulin Market Status (2013-2017)
- 7.1.7 Australia Biosimilar Insulin Market Status (2013-2017)

### 7.2 Asia Pacific Biosimilar Insulin Market Status by Manufacturers

### 7.3 Asia Pacific Biosimilar Insulin Market Status by Type (2013-2017)

- 7.3.1 Asia Pacific Biosimilar Insulin Sales by Type (2013-2017)
- 7.3.2 Asia Pacific Biosimilar Insulin Revenue by Type (2013-2017)

### 7.4 Asia Pacific Biosimilar Insulin Market Status by Downstream Industry (2013-2017)

## **CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

### 8.1 Latin America Biosimilar Insulin Market Status by Countries

- 8.1.1 Latin America Biosimilar Insulin Sales by Countries (2013-2017)
- 8.1.2 Latin America Biosimilar Insulin Revenue by Countries (2013-2017)
- 8.1.3 Brazil Biosimilar Insulin Market Status (2013-2017)
- 8.1.4 Argentina Biosimilar Insulin Market Status (2013-2017)
- 8.1.5 Colombia Biosimilar Insulin Market Status (2013-2017)

### 8.2 Latin America Biosimilar Insulin Market Status by Manufacturers

### 8.3 Latin America Biosimilar Insulin Market Status by Type (2013-2017)

- 8.3.1 Latin America Biosimilar Insulin Sales by Type (2013-2017)
- 8.3.2 Latin America Biosimilar Insulin Revenue by Type (2013-2017)

### 8.4 Latin America Biosimilar Insulin Market Status by Downstream Industry (2013-2017)

## **CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY**

### 9.1 Middle East and Africa Biosimilar Insulin Market Status by Countries

- 9.1.1 Middle East and Africa Biosimilar Insulin Sales by Countries (2013-2017)
- 9.1.2 Middle East and Africa Biosimilar Insulin Revenue by Countries (2013-2017)
- 9.1.3 Middle East Biosimilar Insulin Market Status (2013-2017)
- 9.1.4 Africa Biosimilar Insulin Market Status (2013-2017)

- 9.2 Middle East and Africa Biosimilar Insulin Market Status by Manufacturers
- 9.3 Middle East and Africa Biosimilar Insulin Market Status by Type (2013-2017)
  - 9.3.1 Middle East and Africa Biosimilar Insulin Sales by Type (2013-2017)
  - 9.3.2 Middle East and Africa Biosimilar Insulin Revenue by Type (2013-2017)
- 9.4 Middle East and Africa Biosimilar Insulin Market Status by Downstream Industry (2013-2017)

## **CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF BIOSIMILAR INSULIN**

- 10.1 Global Economy Situation and Trend Overview
- 10.2 Biosimilar Insulin Downstream Industry Situation and Trend Overview

## **CHAPTER 11 BIOSIMILAR INSULIN MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS**

- 11.1 Production Volume of Biosimilar Insulin by Major Manufacturers
- 11.2 Production Value of Biosimilar Insulin by Major Manufacturers
- 11.3 Basic Information of Biosimilar Insulin by Major Manufacturers
  - 11.3.1 Headquarters Location and Established Time of Biosimilar Insulin Major Manufacturer
  - 11.3.2 Employees and Revenue Level of Biosimilar Insulin Major Manufacturer
- 11.4 Market Competition News and Trend
  - 11.4.1 Merger, Consolidation or Acquisition News
  - 11.4.2 Investment or Disinvestment News
  - 11.4.3 New Product Development and Launch

## **CHAPTER 12 BIOSIMILAR INSULIN MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

- 12.1 Pfizer
  - 12.1.1 Company profile
  - 12.1.2 Representative Biosimilar Insulin Product
  - 12.1.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Pfizer
- 12.2 Biogenomics
  - 12.2.1 Company profile
  - 12.2.2 Representative Biosimilar Insulin Product
  - 12.2.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Biogenomics
- 12.3 Eli Lilly
  - 12.3.1 Company profile

- 12.3.2 Representative Biosimilar Insulin Product
- 12.3.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Eli Lilly
- 12.4 Gan&Lee Pharmaceuticals
  - 12.4.1 Company profile
  - 12.4.2 Representative Biosimilar Insulin Product
  - 12.4.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Gan&Lee Pharmaceuticals
- 12.5 Geropharm
  - 12.5.1 Company profile
  - 12.5.2 Representative Biosimilar Insulin Product
  - 12.5.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Geropharm
- 12.6 Julphar Gulf Pharmaceutical Industries
  - 12.6.1 Company profile
  - 12.6.2 Representative Biosimilar Insulin Product
  - 12.6.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Julphar Gulf Pharmaceutical Industries
- 12.7 Paras Biopharmaceuticals
  - 12.7.1 Company profile
  - 12.7.2 Representative Biosimilar Insulin Product
  - 12.7.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Paras Biopharmaceuticals
- 12.8 Samsung Bioepis
  - 12.8.1 Company profile
  - 12.8.2 Representative Biosimilar Insulin Product
  - 12.8.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Samsung Bioepis
- 12.9 Sedico
  - 12.9.1 Company profile
  - 12.9.2 Representative Biosimilar Insulin Product
  - 12.9.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Sedico
- 12.10 Wockhardt
  - 12.10.1 Company profile
  - 12.10.2 Representative Biosimilar Insulin Product
  - 12.10.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Wockhardt
- 12.11 Teva Pharmaceuticals
  - 12.11.1 Company profile
  - 12.11.2 Representative Biosimilar Insulin Product
  - 12.11.3 Biosimilar Insulin Sales, Revenue, Price and Gross Margin of Teva Pharmaceuticals



## **CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOSIMILAR INSULIN**

- 13.1 Industry Chain of Biosimilar Insulin
- 13.2 Upstream Market and Representative Companies Analysis
- 13.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF BIOSIMILAR INSULIN**

- 14.1 Cost Structure Analysis of Biosimilar Insulin
- 14.2 Raw Materials Cost Analysis of Biosimilar Insulin
- 14.3 Labor Cost Analysis of Biosimilar Insulin
- 14.4 Manufacturing Expenses Analysis of Biosimilar Insulin

## **CHAPTER 15 REPORT CONCLUSION**

## **CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE**

- 16.1 Methodology/Research Approach
  - 16.1.1 Research Programs/Design
  - 16.1.2 Market Size Estimation
  - 16.1.3 Market Breakdown and Data Triangulation
- 16.2 Data Source
  - 16.2.1 Secondary Sources
  - 16.2.2 Primary Sources
- 16.3 Reference



## I would like to order

Product name: Biosimilar Insulin-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data

Product link: <https://marketpublishers.com/r/B1A8EC59F0AEN.html>

Price: US\$ 3,680.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B1A8EC59F0AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970